摘要
目的 总结吉非替尼 (Iressa)治疗复发性非小细胞肺癌患者的临床疗效。方法 2 9例经放化疗治疗失败的非小细胞肺癌进入本研究 ,其中 3例肿瘤局限于胸腔内 ,2 6例已有远处转移。Iressa剂量为 2 5 0mg/次 ,口服 ,每天 1次。全组服药的中位时间为 5个月。 结果 主要的毒副作用是皮疹 ,共有 12例发生皮疹 ,占全组的 41.4%。其它的副作用有腹泻 2例 ,心动过缓 1例 ,转氨酶升高 1例。治疗后获完全缓解 1例 ,部分缓解 7例 ,稳定 12例 ,进展 9例。全组有效率为 2 7.5 9%,疾病控制率为 68.97%。中位生存时间为 5 .5个月 ( 1～ 19个月 ) ,中位肿瘤进展时间为 6.5个月 ,1年生存率为 44 .83 %。结论 Iressa对放化疗治疗失败的非小细胞肺癌患者有明显的抗肿瘤作用 ,能明显改善症状 。
Objective To summarize the clinical results of Iressa in the treatment of patients with non small cell lung cancer (NSCLC) who failed prior chemotherapy and radiotherapy. Methods Twenty nine patients with NSCLC, who failed prior chemotherapy and radiotherapy, were registered in this open clinical trial. Prior to Iressa therapy, 26 patients were in stage Ⅳ, 3 patients in stage ⅢB. Iressa was administered orally at 250 mg, once a day until cancer progressed or severe toxicity occured. The median time for administration of Iressa was 5 months. Results The main toxicity of Iressa was skin toxicity (rash). Twelve cases had rash with 41.4% of the whole group. Two cases had diarrhea, 1 case had bradycardia and 1 case had elevation of transaminase. Among the 29 patients, one patient got complete response (CR), 7 partial response (PR), 12 stable disease (SD) and 9 progression disease (PD). The response rate was 27.59% and disease control rate including both tumor response and stable disease was 68.97%. The median survival time was 5.5 months (1 19 months). Median time to progression (TTP) was 6.5 months. The 1 year survival rate was 44.83%. Conclusion Iressa is effective and tolerable for the patients with NSCLC who failed prior chemotherapy and radiotherapy. It can remarkably improve symptoms and prolong survival time of NSCLC patients.
出处
《中国肺癌杂志》
CAS
2004年第4期321-324,共4页
Chinese Journal of Lung Cancer
